Literature DB >> 28175945

[Neuroborreliosis - Diagnostics, treatment and course].

R Dersch1, S Rauer2.   

Abstract

Lyme neuroborreliosis is a tick-borne infectious disease caused by the spirochete bacterium Borrelia burgdorferi sensu lato. Clinical manifestations are classified as early and late Lyme neuroborreliosis. Early manifestations are much more common than late manifestations. Serological testing should only be performed when typical neurological symptoms are present because false positive results are common due to a high seroprevalence in the population. Cerebrospinal fluid (CSF) analysis should be performed if Lyme neuroborreliosis is suspected. A systematic review found similar effects of beta-lactam antibiotics and doxycycline regarding the outcome of neurological symptoms and adverse effects. The prognosis after antibiotic treatment is usually favorable and residual symptoms can rarely persist. Impairments in quality of life, fatigue, depression and cognitive impairment are not more frequent in patients after treatment of Lyme neuroborreliosis than in the normal healthy population.

Entities:  

Keywords:  Evidence-based medicine; Lyme disease; Lyme neuroborreliosis; Quality of life; Treatment

Mesh:

Substances:

Year:  2017        PMID: 28175945     DOI: 10.1007/s00115-016-0263-1

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  47 in total

1.  Discriminating Lyme neuroborreliosis from other neuroinflammatory diseases by levels of CXCL13 in cerebrospinal fluid.

Authors:  N D van Burgel; F Bakels; A C M Kroes; A P van Dam
Journal:  J Clin Microbiol       Date:  2011-03-02       Impact factor: 5.948

Review 2.  Efficacy and safety of pharmacological treatments for acute Lyme neuroborreliosis - a systematic review.

Authors:  R Dersch; M H Freitag; S Schmidt; H Sommer; S Rauer; J J Meerpohl
Journal:  Eur J Neurol       Date:  2015-06-08       Impact factor: 6.089

Review 3.  [Neurologic forms of Lyme disease. 12 cases].

Authors:  F Viader; A M Poncelet; F Chapon; J P Thenint; B Dupuy; P Morin; B Lechevalier
Journal:  Rev Neurol (Paris)       Date:  1989       Impact factor: 2.607

4.  Foci of tick-borne diseases in southwest Germany.

Authors:  Rainer Oehme; Kathrin Hartelt; Hannelore Backe; Stefan Brockmann; Peter Kimmig
Journal:  Int J Med Microbiol       Date:  2002-06       Impact factor: 3.473

5.  Quality of life, fatigue, depression and cognitive impairment in Lyme neuroborreliosis.

Authors:  Rick Dersch; Antonia A Sarnes; Monika Maul; Tilman Hottenrott; Annette Baumgartner; Sebastian Rauer; Oliver Stich
Journal:  J Neurol       Date:  2015-09-26       Impact factor: 4.849

6.  Duration of antibiotic treatment in disseminated Lyme borreliosis: a double-blind, randomized, placebo-controlled, multicenter clinical study.

Authors:  J Oksi; J Nikoskelainen; H Hiekkanen; A Lauhio; M Peltomaa; A Pitkäranta; D Nyman; H Granlund; S-A Carlsson; I Seppälä; V Valtonen; M Viljanen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-08       Impact factor: 3.267

7.  Borrelia burgdorferi-specific intrathecal antibody production in neuroborreliosis: a follow-up study.

Authors:  S Hammers-Berggren; K Hansen; A M Lebech; M Karlsson
Journal:  Neurology       Date:  1993-01       Impact factor: 9.910

Review 8.  Prevalence and spectrum of residual symptoms in Lyme neuroborreliosis after pharmacological treatment: a systematic review.

Authors:  R Dersch; H Sommer; S Rauer; J J Meerpohl
Journal:  J Neurol       Date:  2015-10-12       Impact factor: 4.849

9.  Relevance of cerebrospinal fluid variables for early diagnosis of neuroborreliosis.

Authors:  H Tumani; G Nölker; H Reiber
Journal:  Neurology       Date:  1995-09       Impact factor: 9.910

10.  Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  J J Halperin; E D Shapiro; E Logigian; A L Belman; L Dotevall; G P Wormser; L Krupp; G Gronseth; C T Bever
Journal:  Neurology       Date:  2007-05-23       Impact factor: 9.910

View more
  1 in total

1.  Do patients with schizophreniform and bipolar disorders show an intrathecal, polyspecific, antiviral immune response? A pilot study.

Authors:  Dominique Endres; Daniela Huzly; Rick Dersch; Oliver Stich; Benjamin Berger; Florian Schuchardt; Evgeniy Perlov; Nils Venhoff; Sabine Hellwig; Bernd L Fiebich; Daniel Erny; Tilman Hottenrott; Ludger Tebartz van Elst
Journal:  Fluids Barriers CNS       Date:  2017-12-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.